Cargando…
Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
INTRODUCTION: Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. OBJECTIVES: To describe the clinical, epidemiological, radiological and analytical characteristics of patients with AF admitt...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579895/ https://www.ncbi.nlm.nih.gov/pubmed/36275872 http://dx.doi.org/10.1016/j.medcle.2022.01.020 |
_version_ | 1784812280844648448 |
---|---|
author | Azaña Gómez, Javier Pérez-Belmonte, Luis M. Rubio-Rivas, Manuel Bascuñana, José Quirós-López, Raúl Taboada Martínez, María Luisa Montero Hernandez, Esther Roque-Rojas, Fernando Méndez-Bailón, Manuel Gómez-Huelgas, Ricardo |
author_facet | Azaña Gómez, Javier Pérez-Belmonte, Luis M. Rubio-Rivas, Manuel Bascuñana, José Quirós-López, Raúl Taboada Martínez, María Luisa Montero Hernandez, Esther Roque-Rojas, Fernando Méndez-Bailón, Manuel Gómez-Huelgas, Ricardo |
author_sort | Azaña Gómez, Javier |
collection | PubMed |
description | INTRODUCTION: Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. OBJECTIVES: To describe the clinical, epidemiological, radiological and analytical characteristics of patients with AF admitted for COVID-19 in Spain. Secondarily, we aim to identify those variables associated with mortality and poor prognosis of COVID-19 in patients with AF. METHODS: Retrospective, observational, multicenter, nationwide, retrospective study of patients hospitalized for COVID-19 from March 1 to October 1, 2020. Data were obtained from the SEMI-COVID-19 Registry of the Spanish Society of Internal Medicine (SEMI) in which 150 Spanish hospitals participate. RESULTS: Between March 1 and October 1, 2020, data from a total of 16,461 patients were entered into the SEMI-COVID-19 registry. 1,816 (11%) had a history of AF and the number of deaths among AF patients amounted to 738 (41%). Regarding clinical characteristics, deceased patients were admitted with a higher heart rate (88.38 vs 84.95; p > 0.01), with a higher percentage of respiratory failure (67.2% vs 20.1%; p < 0.01) and high tachypnea (58% vs 30%; p < 0.01). The comorbidities that presented statistically significant differences in the deceased group were: age, hypertension and diabetes with target organ involvement. There was also a higher prevalence of a history of cardiovascular disease in the deceased. On multivariate analysis, DOACs treatment had a protective role for mortality (OR:0,597) IC (0,402-0,888 ; p = 0.011). CONCLUSIONS: Previous treatment with DOACs and DOACs treatment during admission seem to have a protective role in patients with AF, although this fact should be verified in prospective studies. |
format | Online Article Text |
id | pubmed-9579895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95798952022-10-19 Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry Azaña Gómez, Javier Pérez-Belmonte, Luis M. Rubio-Rivas, Manuel Bascuñana, José Quirós-López, Raúl Taboada Martínez, María Luisa Montero Hernandez, Esther Roque-Rojas, Fernando Méndez-Bailón, Manuel Gómez-Huelgas, Ricardo Med Clin (Engl Ed) Original Article INTRODUCTION: Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. OBJECTIVES: To describe the clinical, epidemiological, radiological and analytical characteristics of patients with AF admitted for COVID-19 in Spain. Secondarily, we aim to identify those variables associated with mortality and poor prognosis of COVID-19 in patients with AF. METHODS: Retrospective, observational, multicenter, nationwide, retrospective study of patients hospitalized for COVID-19 from March 1 to October 1, 2020. Data were obtained from the SEMI-COVID-19 Registry of the Spanish Society of Internal Medicine (SEMI) in which 150 Spanish hospitals participate. RESULTS: Between March 1 and October 1, 2020, data from a total of 16,461 patients were entered into the SEMI-COVID-19 registry. 1,816 (11%) had a history of AF and the number of deaths among AF patients amounted to 738 (41%). Regarding clinical characteristics, deceased patients were admitted with a higher heart rate (88.38 vs 84.95; p > 0.01), with a higher percentage of respiratory failure (67.2% vs 20.1%; p < 0.01) and high tachypnea (58% vs 30%; p < 0.01). The comorbidities that presented statistically significant differences in the deceased group were: age, hypertension and diabetes with target organ involvement. There was also a higher prevalence of a history of cardiovascular disease in the deceased. On multivariate analysis, DOACs treatment had a protective role for mortality (OR:0,597) IC (0,402-0,888 ; p = 0.011). CONCLUSIONS: Previous treatment with DOACs and DOACs treatment during admission seem to have a protective role in patients with AF, although this fact should be verified in prospective studies. Published by Elsevier España, S.L.U. 2022-11-25 2022-10-13 /pmc/articles/PMC9579895/ /pubmed/36275872 http://dx.doi.org/10.1016/j.medcle.2022.01.020 Text en © 2022 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Azaña Gómez, Javier Pérez-Belmonte, Luis M. Rubio-Rivas, Manuel Bascuñana, José Quirós-López, Raúl Taboada Martínez, María Luisa Montero Hernandez, Esther Roque-Rojas, Fernando Méndez-Bailón, Manuel Gómez-Huelgas, Ricardo Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry |
title | Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry |
title_full | Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry |
title_fullStr | Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry |
title_full_unstemmed | Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry |
title_short | Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry |
title_sort | mortality risk factors in patients with sars-cov-2 infection and atrial fibrillation: data from the semi-covid-19 registry |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579895/ https://www.ncbi.nlm.nih.gov/pubmed/36275872 http://dx.doi.org/10.1016/j.medcle.2022.01.020 |
work_keys_str_mv | AT azanagomezjavier mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT perezbelmonteluism mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT rubiorivasmanuel mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT bascunanajose mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT quiroslopezraul mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT taboadamartinezmarialuisa mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT monterohernandezesther mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT roquerojasfernando mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT mendezbailonmanuel mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT gomezhuelgasricardo mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry AT mortalityriskfactorsinpatientswithsarscov2infectionandatrialfibrillationdatafromthesemicovid19registry |